ACEIs and ARBs and Their Correlation with COVID-19: A Review.
Awgichew Shewasinad YehualashetTeshome Fentik BelachewPublished in: Infection and drug resistance (2020)
Although some animal studies suggested that the use of ACEIs/ARBs could contribute for the prevention and treatment of the effects of the COVID-19 infection, there are also contradictory scenarios indicating that their use may exacerbate the deleterious conditions of the infection. As a result of the paradoxical issue of using ACEIs/ARBs during COVID-19, it is still an area requiring extended investigation to prove. Additionally, a trial evidence of their efficacy and the possible benefit risk analysis of these conventional drugs during COVID-19 in connection with other comorbidities like hypertension, heart failure, and renal disease associated with diabetes should also be addressed.
Keyphrases
- heart failure
- coronavirus disease
- blood pressure
- sars cov
- type diabetes
- cardiovascular disease
- climate change
- clinical trial
- study protocol
- left ventricular
- phase iii
- randomized controlled trial
- phase ii
- glycemic control
- metabolic syndrome
- case control
- acute heart failure
- arterial hypertension
- smoking cessation
- double blind